We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05199285
Title Nivolumab and Ipilimumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Liver Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama- Birmingham RECRUITING Birmingham Alabama 35233 United States Details
University of Miami Miller School of Medicine-Sylvester Cancer Center RECRUITING Miami Florida 33136 United States Details
Emory University Hospital/Winship Cancer Institute NOT_YET_RECRUITING Atlanta Georgia 30322 United States Details
Mayo Clinic in Rochester NOT_YET_RECRUITING Rochester Minnesota 55905 United States Details
Rutgers Cancer Institute of New Jersey RECRUITING New Brunswick New Jersey 08903 United States Details
Vanderbilt University/Ingram Cancer Center RECRUITING Nashville Tennessee 37232 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field